Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage I-IVB squamous cell carcinoma of the nasopharynx~  * WHO I-III~ * No stage IVC disease~ * No evidence of distant metastasis~* Measurable or evaluable disease~* Must have been treated with primary radiotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* White blood cell count (WBC) at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine no greater than 1.6 mg/dL~* Creatinine clearance at least 60 mL/min~Other~* Not pregnant (If stage T2b or greater or node-positive disease)~* Negative pregnancy test (If stage T2b or greater or node-positive disease)~* No other prior head and neck cancer~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* No active untreated infection~* No other major medical or psychiatric illness that would preclude study entry~* Nutritional and general physical condition compatible with radiotherapy NOTE: \*If stage T2b or greater or node-positive disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* More than 6 months since prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* More than 6 months since prior radiotherapy for head and neck cancer~Surgery~* No prior head and neck surgery to the primary tumor or lymph nodes except incisional or excisional biopsies~Other~* No other concurrent experimental therapy for cancer~* No amifostine or pilocarpine during or for 3 months after radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMRT +/- chemotherapy (Type: EXPERIMENTAL): Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+

Based on this trial design, predict the completion outcome and termination type (if applicable).